Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
Aprea Therapeutics announced that an abstract detailing early results from the first-in-human Phase 1 study of WEE1 inhibitor APR-1051 has been accepted for presentation at the 2026 ASCO Annual Meeting. The poster session is scheduled for May 30, 2026, in Chicago, with Dr. Shiraj Sen of NEXT Oncology Dallas serving as the presenting author.
Key figures
- Drug Name
- APR-1051
- Phase Of Trial
- phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.